- Home
- KYMR vs ENSG Comparison
KYMR vs ENSG Comparison
Compare KYMR & ENSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYMR | ENSG |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.4B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | KYMR | ENSG |
|---|---|---|
| Price | $104.20 | $176.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 5 |
| Target Price | $107.72 | ★ $202.60 |
| AVG Volume (30 Days) | ★ 558.9K | 452.5K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.14% |
| EPS Growth | N/A | ★ 14.06 |
| EPS | N/A | ★ 3.35 |
| Revenue | $39,211,000.00 | ★ $5,057,841,000.00 |
| Revenue This Year | $10.61 | $17.07 |
| Revenue Next Year | $8.17 | $9.49 |
| P/E Ratio | ★ N/A | $52.90 |
| Revenue Growth | N/A | ★ 18.72 |
| 52 Week Low | $36.88 | $141.58 |
| 52 Week High | $130.05 | $218.00 |
Technical Indicators
Market Signals| Indicator | KYMR | ENSG |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.59 |
| Support Level | N/A | $168.55 |
| Resistance Level | N/A | $184.02 |
| Average True Range (ATR) | 0.00 | 4.36 |
| MACD | 0.00 | 0.30 |
| Stochastic Oscillator | 0.00 | 42.83 |
Price Performance
Historical ComparisonAbout KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
About ENSG The Ensign Group Inc.
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.